Skip to main content
Retour
MESO logo

Mesoblast Limited

Qualité des données : 100%
MESO
NASDAQ Healthcare Biotechnology
14,02 €
▼ 0,34 € (-2,37%)
Cap. Boursière : 1,80B
Également cotée sous MEOBF OTC
Fourchette du Jour
14,02 € 14,87 €
Fourchette 52 Semaines
9,61 € 21,50 €
Volume
1 227 836
Moyenne 50J / 200J
16,77 € / 15,78 €
Clôture Précédente
14,36 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -17,7 0,4
P/B 3,0 2,9
ROE % -19,0 3,7
Net Margin % -593,9 3,8
Rev Growth 5Y % 23,2 10,0
D/E 0,2 0,2

Points Clés

Revenue grew 23,24% annually over 5 years — strong growth
Debt/Equity of 0,21 — conservative balance sheet
Negative free cash flow of -50,68M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 168,15%
Capital efficient — spends only 4,24% of revenue on capex

Croissance

Revenue Growth (5Y)
23,24%
Revenue (1Y)191,39%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-18,95%
ROIC-6,45%
Net Margin-593,92%
Op. Margin-363,08%

Sécurité

Debt / Equity
0,21
Current Ratio1,99
Interest Coverage-2,72

Valorisation

P/E Ratio
-17,66
P/B Ratio3,02
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 191,39% Revenue Growth (3Y) 51,42%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 23,24% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 17,20M Net Income (TTM) -102,14M
ROE -18,95% ROA -13,02%
Gross Margin 70,17% Operating Margin -363,08%
Net Margin -593,92% Free Cash Flow (TTM) -50,68M
ROIC -6,45% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,21 Current Ratio 1,99
Interest Coverage -2,72 Dividend Yield 0,00%
Valuation
P/E Ratio -17,66 P/B Ratio 3,02
P/S Ratio 104,91 PEG Ratio 2,44
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,80B Enterprise Value 1,77B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 17,20M 5,90M 7,50M 10,21M 7,46M
Net Income -102,14M -87,96M -81,89M -91,35M -98,81M
EPS (Diluted) -0,84 -0,89 -0,98 -1,30 -1,60
Gross Profit 12,07M -35,17M -47,42M -53,36M -78,28M
Operating Income -62,44M -84,15M -69,29M -80,57M -109,10M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 784,68M 669,15M 669,42M 662,14M 744,72M
Total Liabilities 187,24M 188,80M 167,58M 165,10M 163,32M
Shareholders' Equity 597,44M 480,36M 501,84M 497,04M 581,40M
Total Debt 128,16M 118,92M 116,50M 106,91M 105,50M
Cash & Equivalents 161,16M 62,56M 70,92M 60,03M 136,88M
Current Assets 204,35M 86,46M 81,66M 69,84M 148,23M
Current Liabilities 102,63M 73,24M 41,98M 51,37M 94,27M